JW Life Science, a medical fluid maker, said Tuesday that it would speed up entering the Chinese market through preliminary consulting on manufacturing and quality control. 

JW Life Science, a subsidiary of JW Holdings, was selected as the beneficiary of the pilot project run by the Korea Health Industry Development Institute (KHIDI), called the “Project to support Korean drugmakers’ advance abroad throughout the life cycle,” in April. 

Under the project, KHIDI under the Ministry of Health and Welfare helps Korean pharmaceutical firms advance to foreign markets by providing support from the state of development planning and licensing of export drugs to their manufacture and finding partners for successful localization through prior consulting.

Based on a final report at the end of last month, KHIDI will provide 50 percent of all project expenditure for JW Life Science, the company said. 

JW is preparing additional data to meet China’s requirements based on its entry to Europe with its comprehensive nutrient fluid product, “Winuf.” Besides, the company has agreed to export the related technology to China’s Shandong Luoxin Pharmaceutical Group.

China’s market for IV fluids grew 25.5 percent between 2017 and 2019, compared with the global average of 9.1 percent. 

As the Chinese market requires strict chemistry manufacturing and control (CMC), the company will focus on supplementing this area based on local consulting. 

“As China’s pharmaceutical market is more difficult to enter than even the European and U.S. markets due to regulations, local consulting is necessary,” a JW official said. “We will strive to produce results in a short period, now that we pried open the market through the signing of tech export and finished products' supply.”